One platform for all researcher needs
AI-powered academic writing assistant
Your #1 AI companion for literature search
AI tool for graphics, illustrations, and artwork
Unlock unlimited use of all AI tools with the Editage All Access membership.
Explore Editage All Accesshttps://doi.org/10.1182/blood.v130.suppl_1.322.322
Copy DOI Journal: Blood |  Publication Date: Jun 25, 2021 |
Affiliation: University of Insubria, Royal Brisbane and Women's Hospital, University of Florence, Ziekenhuisnetwerk Antwerpen Stuivenberg, University of Naples Federico II, Délégation Paris 7, Policlinico San Matteo Fondazione, Autonomous University of Barcelona, The University of Texas MD Anderson Cancer Center, Novartis (Switzerland), University of Yamanashi, Charité - Universitätsmedizin Berlin, Hospital Ramos Mejía, Novartis (France), The University of Texas Health Science Center at San Antonio, Semmelweis University, Guy's and St Thomas' NHS Foundation Trust, Foundation Center, Saint Agnes Hospital, Osaka City University, Johannes Wesling Klinikum MindenResults from the 208-Week (4-Year) Follow-up of RESPONSE Trial, a Phase 3 Study Comparing Ruxolitinib (Rux) with Best Available Therapy (BAT) for the Treatment of Polycythemia Vera (PV)
Sign-in/Register to access full text options 
Free) Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
